Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Signal Transducer and Activator of Transcription 5 (STAT5) is implicated in human cancers, including acute myeloid leukemia and prostate cancer.
• STAT5 remains an under-investigated therapeutic target compared to STAT3, despite its role in cancer progression.

Purpose of the Study:

• To identify potent and selective direct small molecule inhibitors of STAT5.
• To evaluate the therapeutic potential of novel STAT5 inhibitors in cancer cell models.

Main Methods:

• In vitro screening of a focused library of SH2 domain binding salicylic acid-containing inhibitors against STAT5, STAT3, and STAT1.
• Assays to determine inhibitor potency (K(i)) and selectivity.
• Evaluation of lead compounds in human leukemia cell lines (K562, MV-4-11) for apoptosis induction and STAT5 phosphorylation inhibition.
• Assessment of STAT5 target gene inhibition (cyclin D1, cyclin D2, C-MYC, MCL-1).
• Cytotoxicity testing in normal bone marrow cells.

Main Results:

• Identification of potent (K(i) < 5 μM) and STAT5-selective inhibitors (BP-1-107, BP-1-108, SF-1-087, SF-1-088).
• Lead agents induced apoptosis (IC(50)s ∼ 20 μM) in leukemia cells, correlating with STAT5 phosphorylation suppression and inhibition of STAT5 target genes.
• BP-1-108 demonstrated negligible cytotoxicity in normal bone marrow cells lacking activated STAT5.

Conclusions:

• The study reports novel, potent, and selective small molecule, non-phosphorylated inhibitors of STAT5.
• These inhibitors represent promising therapeutic candidates for STAT5-driven cancers.
• The findings highlight the potential of targeting STAT5 for cancer treatment.